VADs Set To Enter Big Leagues With St. Jude's Plan To Acquire Thoratec

St. Jude Medical says it will pay $3.4 billion to own ventricular-assist device leader Thoratec, pointing to significant synergies in the heart failure and interventional cardiology markets. The deal would thrust VADs into a diversified cardiology firm for the first time, and it includes a "go-shop" period that leaves an opening for other big device firms to enter competing bids.

St. Jude Medical Inc. plans to be the first of the big cardiovascular device companies to sell ventricular assist devices after agreeing to buy leading VAD-maker Thoratec Corp. But there is a possibility that another rival could swoop in to take its place.

The companies announced a definitive agreement on July 22 for St. Jude to acquire Thoratec for about $3.4 billion in cash, net of cash acquired, or $63.50 per share, a premium of 40

More from Archive

More from Medtech Insight